Alembic Pharmaceuticals informs about press release

03 Jul 2023 Evaluate

With reference to its earlier communication dated 17th April, 2023, Alembic Pharmaceuticals has informed the exchange that the Company has received various US Food & Drug Administration (USFDA) (Tentative or Final) Product Approvals during the quarter ended 30th June, 2023. The summary statement giving brief of all product approvals received during the quarter ended 30th June, 2023 is enclosed. Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.

The above information is a part of company’s filings submitted to BSE.

Alembic Pharma Share Price

761.75 -3.10 (-0.41%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×